EGFR and non-small cell lung carcinoma: Osimertinib (AZD9291) (47), a third-generation irreversible EGFR TKI currently approved for clinical use, received accelerated FDA approval in November 2015 for second-line treatment of NSCLC, and, subsequently, in 2018, FDA approval for first-line treatment.